Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols


EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.


Title Abstract Investigator
EDRN Breast and Ovary Cancer CVC, Study 1: Preliminary validation of breast cancer early detection biomarker candidates from our WHI discovery project There is an urgent need for breast cancer early detection biomarkers given that none are currently available and given the considerable public health ... Li, Christopher
EDRN Breast and Ovary Cancer CVC, Study 2: Phase 3 retrospective validation of ovarian cancer early detection markers in serial preclinical samples from the PLCO trial Over 70% of women with ovarian/fallopian tube cancer (OC) are diagnosed with advanced stage disease which has a 5-year relative survival rate of 30%. Five-year ... Li, Christopher
EDRN Breast and Ovary Cancer CVC, Study 3: Phase 3 Validation of screening decision rules in preclinical UKCTOCS serial samples We will collaborate with investigators from University College London to test a screening decision rule in preclinical serial samples from the U.K. ... Li, Christopher
EDRN Breast and Ovary Cancer CVC, Study 4: Phase 3 Validation of Ovarian Cancer Serum Markers in Preclinical WHI Samples The WHI offers an opportunity to evaluate ovarian cancer markers and screening decision rules developed and validated in EDRN CVC Studies 2 and 3 in women who ... Li, Christopher
EDRN Informatics Pilot Project Bigbee, William L.
EDRN Longitudinal Serum Biorepository Four percent of EDRN Registry mutation carriers developed cancer within a year after beginning follow-up in this registry; within 2 years, 10% had developed ... Lynch, Henry
EDRN Pre-Validation of Metabolic Biomarkers of Prostate Cancer: Follow up EDRN Challenge The goal of this EDRN set-asides proposal is to carry out pre-validation studies on sarcosine as a metabolomic biomarker of prostate cancer in urine. Not only ... Chinnaiyan, Arul M.
EDRN Pre-Validation of Multiplex Biomarker in Urine The goal of this proposal is to begin to establish an EDRN “pre-validation” trial of a multiplex set of transcripts, including the ETS gene fusions, in ... Chinnaiyan, Arul M.
EDRN Resource Network Exchange Srivastava, Sudhir
EDRN-WHI Pre-Clinical Colon Ca Specimens Specifically, it is proposed to assess plasma proteins from postmenopausal women diagnosed with colon cancer within a span of 18 months after year-3 OS blood ... Hanash, Samir
Early Detection Research Network Registry for Hereditary Cancer The EDRN High Risk Registry (HRR)recruits individuals that carry germline mutations for hereditary cancer syndromes, who are willing to participate in ... Lynch, Henry
Early Detection and Prognosis of Hepatocellular Carcinoma Volk, Michael L.
Early Detection of Breast Cancer Using Autoantibody Markers To identify large numbers of antigens that can be used to recognize the presence of cancer by detecting antibodies to tumor proteins in the serum of the test ... Tainsky, Michael A.
Early Detection of Cancer by Affinity Mass Spectrometry-Set Aside funds A.   RATIONALE The recent introduction of multiple reaction monitoring capabilities offers unprecedented capability to the research arsenal available to ... Semmes, John
Early Detection of Urinary Bladder Cancer Czerniak, Bogdan
Early Diagnosis of Pancreatic Cancer-Network Collaborative Studies Determining and quantifying the types of mucin core proteins to which CA19-9 is attached will result in assays with improved performance characteristics ... Hollingsworth, Michael
Early Molecular Detection of Invasive Bladder Cancer by Urine Examination Czerniak, Bogdan
Early detection of liver cancer and hepatitis Block, Timothy
Ecogenetic Study of Lung Cancer Spitz, Margaret R.
Establishment of a serum standard for use in high-throughput proteomic Semmes, John
Expression based markers for breast cancer detection Marks, Jeffrey
GLNE 003: Preliminary Validation of Biomarkers Predictive of Barrett’s Esophagus Progression to Dysplasia and Adenocarcinoma    Recognizing that novel potential biomarkers are continually being identified and will need to be validated in a rapid, efficient, and scientifically ... Brenner, Dean
GSTP1 Methylation Sidransky, David
Glycoprotein Biomarkers for the Early Detection of Aggressive Prostate Cancer The Early Detection Research Network of the NCI is charged with the discovery, development and validation of biomarkers for early detection and prognosis ... Zhang, Hui L.
HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum Lynch, Henry
Hepatocellular carcinoma Early Detection Strategy study Marrero, Jorge
Hereditary Cancer Institute family study specimen bank Lynch, Henry
High-Throughput Evaluation of Breast Cancer Markers The objective of this study is to use a combination of AMT proteomics and ELISA microarray testing to discover and validate novel biomarkers for breast cancer. Zangar, Richard (Rick) C.
Hollingsworth - Aggressive vs Indolent 2012 Study Overview. We will examine DNA extracted from FFPE sections from approximately 200 different surgically resected primary pancreatic tumors from the UNMC ... Hollingsworth, Michael
Hollingsworth - Aggressive vs Indolent 2012 (357) Study Overview. We will examine DNA extracted from FFPE sections from approximately 200 different surgically resected primary pancreatic tumors from the UNMC ... Hollingsworth, Michael
2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.